As tumors are heterogeneous, and changes in mutation status can occur, it might be possible that some patients who were classified as TNBC at study entry and who subsequently experienced CB during treatment with afatinib may, in fact, have had HER2-positive tumor sites at the time of study treatment. This evidence concerns the gene ERBB2 and neoplasm.